Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 383

Similar articles for PubMed (Select 16121404)


Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma.

Zhou Z, Guan H, Duan X, Kleinerman ES.

Cancer. 2005 Oct 15;104(8):1713-20.


Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.

Ottewell PD, Deux B, Mönkkönen H, Cross S, Coleman RE, Clezardin P, Holen I.

Clin Cancer Res. 2008 Jul 15;14(14):4658-66. doi: 10.1158/1078-0432.CCR-07-1545.


Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.

Lu S, Zhang J, Zhou Z, Liao ML, He WZ, Zhou XY, Li ZM, Xiang JQ, Wang JJ, Chen HQ.

Oncol Rep. 2008 Sep;20(3):581-7.


Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients.

Odri GA, Dumoucel S, Picarda G, Battaglia S, Lamoureux F, Corradini N, Rousseau J, Tirode F, Laud K, Delattre O, Gouin F, Heymann D, Redini F.

Cancer Res. 2010 Oct 1;70(19):7610-9. doi: 10.1158/0008-5472.CAN-09-4272. Epub 2010 Sep 14.


The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.

Peng H, Sohara Y, Moats RA, Nelson MD Jr, Groshen SG, Ye W, Reynolds CP, DeClerck YA.

Cancer Res. 2007 Oct 1;67(19):9346-55.


Effective salvage treatment of recurrent Ewing sarcoma utilizing chemotherapy and zoledronic acid.

Siddiqui T, Marsh Rde W, Allegra C, Whittaker D, Scarborough M, Gibbs P, Zlotecki R, Reith JD, Drane W.

Clin Adv Hematol Oncol. 2010 Jul;8(7):499-504. No abstract available.


Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone.

Ottewell PD, Woodward JK, Lefley DV, Evans CA, Coleman RE, Holen I.

Mol Cancer Ther. 2009 Oct;8(10):2821-32. doi: 10.1158/1535-7163.MCT-09-0462. Epub 2009 Sep 29.


Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.

Ottewell PD, Mönkkönen H, Jones M, Lefley DV, Coleman RE, Holen I.

J Natl Cancer Inst. 2008 Aug 20;100(16):1167-78. doi: 10.1093/jnci/djn240. Epub 2008 Aug 11.


Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms.

Quinn JE, Brown LG, Zhang J, Keller ET, Vessella RL, Corey E.

Prostate Cancer Prostatic Dis. 2005;8(3):253-9.


Nicotine and lipopolysaccharide stimulate the formation of osteoclast-like cells by increasing macrophage colony-stimulating factor and prostaglandin E2 production by osteoblasts.

Tanaka H, Tanabe N, Shoji M, Suzuki N, Katono T, Sato S, Motohashi M, Maeno M.

Life Sci. 2006 Mar 6;78(15):1733-40. Epub 2005 Nov 2.


Induction of cell death by basic fibroblast growth factor in Ewing's sarcoma.

Sturla LM, Westwood G, Selby PJ, Lewis IJ, Burchill SA.

Cancer Res. 2000 Nov 1;60(21):6160-70.


Effect of YM529 on a model of mandibular invasion by oral squamous cell carcinoma in mice.

Cui N, Nomura T, Noma H, Yokoo K, Takagi R, Hashimoto S, Okamoto M, Sato M, Yu G, Guo C, Shibahala T.

Clin Cancer Res. 2005 Apr 1;11(7):2713-9.


The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice.

Tannehill-Gregg SH, Levine AL, Nadella MV, Iguchi H, Rosol TJ.

Clin Exp Metastasis. 2006;23(1):19-31. Epub 2006 May 20.


Intensification therapy with anti-parathyroid hormone-related protein antibody plus zoledronic acid for bone metastases of small cell lung cancer cells in severe combined immunodeficient mice.

Yamada T, Muguruma H, Yano S, Ikuta K, Ogino H, Kakiuchi S, Hanibuchi M, Uehara H, Nishioka Y, Sone S.

Mol Cancer Ther. 2009 Jan;8(1):119-26. doi: 10.1158/1535-7163.MCT-08-0874.


A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model.

Guan H, Zhou Z, Wang H, Jia SF, Liu W, Kleinerman ES.

Clin Cancer Res. 2005 Apr 1;11(7):2662-9.


Adenovirus-E1A gene therapy enhances the in vivo sensitivity of Ewing's sarcoma to VP-16.

Zhou RR, Jia SF, Zhou Z, Wang Y, Bucana CD, Kleinerman ES.

Cancer Gene Ther. 2002 May;9(5):407-13.


Strong inhibition of Ewing tumor xenograft growth by combination of human interferon-alpha or interferon-beta with ifosfamide.

Sancéau J, Poupon MF, Delattre O, Sastre-Garau X, Wietzerbin J.

Oncogene. 2002 Oct 31;21(50):7700-9.


Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis.

González I, Andreu EJ, Panizo A, Inogés S, Fontalba A, Fernández-Luna JL, Gaboli M, Sierrasesúmaga L, Martín-Algarra S, Pardo J, Prósper F, de Alava E.

Clin Cancer Res. 2004 Jan 15;10(2):751-61.


Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells.

Kubo T, Shimose S, Matsuo T, Tanaka K, Yasunaga Y, Sakai A, Ochi M.

J Orthop Res. 2006 Jun;24(6):1138-44.


Review: Ewing sarcoma treatment: a role for bisphosphonates?

Subbiah V, Ludwig JA.

Clin Adv Hematol Oncol. 2010 Jul;8(7):503-4. Review. No abstract available.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk